Revolve Wealth Partners LLC Sells 289 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Revolve Wealth Partners LLC lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 36.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 498 shares of the pharmaceutical company’s stock after selling 289 shares during the quarter. Revolve Wealth Partners LLC’s holdings in Vertex Pharmaceuticals were worth $201,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Czech National Bank grew its stake in shares of Vertex Pharmaceuticals by 6.2% in the 4th quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company’s stock worth $22,486,000 after buying an additional 3,260 shares during the last quarter. Whalen Wealth Management Inc. bought a new stake in Vertex Pharmaceuticals in the third quarter worth $662,000. Mizuho Securities USA LLC grew its stake in shares of Vertex Pharmaceuticals by 289.0% in the third quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company’s stock worth $35,994,000 after acquiring an additional 57,497 shares during the last quarter. Nordea Investment Management AB increased its holdings in shares of Vertex Pharmaceuticals by 19.4% during the fourth quarter. Nordea Investment Management AB now owns 342,429 shares of the pharmaceutical company’s stock valued at $137,783,000 after acquiring an additional 55,739 shares in the last quarter. Finally, Keynote Financial Services LLC purchased a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth about $498,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have weighed in on VRTX shares. Cantor Fitzgerald restated an “overweight” rating and set a $480.00 price objective on shares of Vertex Pharmaceuticals in a research note on Friday, January 24th. Morgan Stanley boosted their price objective on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. StockNews.com downgraded Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 21st. Stifel Nicolaus boosted their price target on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a research note on Monday, December 16th. Finally, Jefferies Financial Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price objective for the company from $500.00 to $550.00 in a research report on Monday, December 9th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $494.76.

Vertex Pharmaceuticals Stock Down 0.7 %

Shares of NASDAQ:VRTX opened at $440.68 on Wednesday. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The stock has a 50 day moving average of $434.90 and a 200 day moving average of $463.98. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.69 billion. During the same period in the prior year, the company posted $3.67 earnings per share. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. Sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.